Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently incarcerated at the Rhode Island Department of Corrections with a scheduled release date at least 28 days after enrollment~* Incarceration length not to have exceeded two years at the time of enrollment~* Heroin dependent with self-reported heroin injection in the month prior to incarceration OR enrollment in a methadone treatment program prior to incarceration for heroin addiction with a history of injection drug use~* Desire to enter methadone treatment upon release and plans to secure funding for methadone treatment after study completion~* History of prior tolerance to methadone~* History of at least one drug-related incarceration~* Speaks English or Spanish~* Plans to remain in Rhode Island for the duration of the study (24 months)~* Ability to provide at least two names of individuals who can verify participant information~Exclusion Criteria:~* Currently receiving methadone at the Rhode Island Department of Corrections~* Currently undergoing a non-narcotic detoxification from illicit opiates at the Rhode Island Department of Corrections~* Plans to leave Rhode Island within the two years following enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Release Initiation MMT (Type: EXPERIMENTAL): Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
- Post Release Initiation of MMT (Type: EXPERIMENTAL): Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
- Standard of Care Plus (Type: ACTIVE_COMPARATOR): Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.

Based on this trial design, predict the completion outcome and termination type (if applicable).